Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial

Tan et al.

http://www.trialsjournal.com/content/11/1/113 (24 November 2010)
Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial

Darrell HS Tan1*, Janet M Raboud1, Rupert Kaul1, Beatriz Grinsztejn2, Pedro Cahn3, Sharon L Walmsley1

Abstract

Background: Although highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related morbidity and mortality, the associated costs, toxicities, and resistance risks make the potential delay of HAART initiation an attractive goal. Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary driver of HIV disease progression.

Methods/Design: The VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial is a multicentre, randomized, fully blinded, clinical trial of twice daily valacyclovir 500 mg versus placebo for delaying the need for initiating HAART among HIV-1, HSV-2 co-infected HAART-naïve adults. 480 participants from Canada, Brazil and Argentina will undergo quarterly clinical follow-up until reaching the composite primary endpoint of having a CD4 + T-cell count ≤ 350 cells/mm$^3$ or initiation of HAART for any reason, whichever occurs first. The primary analysis will use a proportional hazards model, stratified by site, to estimate the relative risk of progression to this endpoint associated with valacyclovir. Secondary analyses will compare the rates of change in CD4 count, median log$_{10}$ HIV viral load, drug-related adverse events, frequency of HSV reactivations, rate of acyclovir-resistant HSV, and quality of life between study arms.

Discussion: Although HIV treatment guidelines continue to evolve, with some authorities recommending earlier HAART among asymptomatic individuals, the potential delay of HAART remains a clinically relevant goal for many. If shown to be of benefit, implementation of the VALIDATE intervention will require careful consideration of both individual patient-level and public health implications.

Trial Registration: Current Controlled Trials ISRCTN66756285 ClinicalTrials.gov NCT00860977
HIV therapy. After acute infection there is an initial profound drop in the CD4-positive T lymphocyte count from levels of > 1000 cells/mm³ to roughly 700 cells/mm³ six months later [1]. Patients then enter a generally asymptomatic period characterized by a steady CD4 count decline of about 50-60 cells/mm³ per year, although this varies according to the HIV RNA viral load set point [2-5]. The risk of opportunistic infection and mortality rises sharply at CD4 counts ≤ 200 cells/mm³. Current guidelines therefore agree that HAART is warranted when the CD4 count falls to 350 cells/mm³ in asymptomatic, non-pregnant adults; debate continues on the role of earlier treatment initiation, with some but not all guidelines recommending treatment at a threshold of 500 cells/mm³ [6-9]. Once HAART is initiated, treatment must be lifelong, because HIV cannot be eradicated, and because treatment interruptions are associated with increased rates of HIV-associated and non-HIV-associated conditions [10].

HSV-2 is among the most common co-infections in HIV, with a prevalence of 52-95%, [11-16] and several important interactions have been observed between these two viruses. First, HSV-2 is associated with increased HIV acquisition and transmission, even in asymptomatic individuals [17-27]. Recent trials of daily acyclovir for HSV-2 suppression, however, did not show a benefit on decreasing HIV acquisition or transmission [28-30]. Persistence of HIV target cells in the genital tract, suboptimal dosing and inadequate adherence may have contributed to the negative results[31]. Second, both symptomatic, clinical recurrences of HSV-2, and asymptomatic shedding of HSV-2 have been clearly associated with increased HIV levels in both genital secretions and plasma[32-35]. Upregulation of HIV replication by HSV gene products such as infected cell protein (ICP)-0, ICP-4, ICP-27 and Us11, and stimulation of the NF-Kappa B pathway may contribute to these increases in HIV viral load [36-40]. Further, clinical trials using both acyclovir and valacyclovir suppressive therapy in co-infected individuals, including 20 men who have sex with men (MSM) in Peru, 140 women in Burkina Faso, and 67 women in Thailand have demonstrated clinically significant, reciprocal decreases in HIV RNA viral load of 0.33-0.53 log₁₀[41-43].

The plasma HIV viral load, in turn, is the major predictor of CD4 cell decline and HIV disease progression, and viral load strata that increase by about 0.5 log copies/mL correlate with increased rates of CD4 decline of roughly 10 cells/mm³/year [2-5]. It follows, then, that HSV-2 suppressive therapy might delay HIV disease progression in HAART-untreated individuals through its effects on the HIV viral load. Indeed, a meta-analysis from the pre-HAART era suggested that > 3200 mg per day of acyclovir offered a significant survival benefit (incidence rate ratio for mortality, 0.81, 95%CI 0.68-0.96), although this effect was largely related to treatment of active herpessvirus disease in individuals with late-stage HIV/AIDS [44]. More recently, the multicentre Partners in Prevention trial from Sub-Saharan Africa has shown that acyclovir 400 mg twice daily was associated with moderately decreased progression to the composite endpoint of CD4 < 200 cells/mm³, HAART initiation, or non-trauma related death (hazard ratio = 0.84, 95%CI 0.71-0.98) [45].

These results bolster interest in the VALIDATE trial, which is addressing related but complementary issues. First, given the conduct of the Partners trial in resource-limited settings, it remains important to study the impact of HSV-2 suppression in co-infected patients from industrialized and middle-income countries. The endpoint of the Partners trial represented a stage of disease that can be avoided in settings where the standard of care is to offer HAART earlier; it is encouraging, therefore, that an exploratory analysis from the Partners trial demonstrated a delay in achieving CD4 < 350 cells/mm³ from acyclovir as well (HR = 0.81, 95%CI 0.71-0.93, p = 0.002). Further, rates of CD4 count decline may be different in Sub-Saharan Africa due to the effects of nutritional status, heightened levels of immune activation (for example, as a result of co- or intercurrent infections), and HIV clade [46-49]. The predominant clades in Sub-Saharan Africa (A, D and C) differ from those in most industrialized countries (B and some others) and in South America (B but some F, C and recombinants)[50,51]. In addition, it should be noted that disease progression was a secondary endpoint of the Partners trial, which was primarily designed to study the impact of HSV-2 suppression on HIV transmission. Finally, VALIDATE is employing valacyclovir instead of acyclovir for HSV-2 suppression, and the dose of 500 mg twice daily has been demonstrated to achieve excellent herpes suppression in clinical trials of HIV, HSV-2 co-infected adults [41,42]. Valacyclovir is the pro-drug of acyclovir, and may offer advantages over acyclovir owing to an improved bioavailability (54.5% versus 15-30%) and lower pill burden[52].

Chronic suppressive therapy with valacyclovir is safe, well-tolerated and already in widespread use to prevent HSV outbreaks in those with frequent (five times a year or more) clinical reactivation. However, up to 90% of individuals with HSV-2 infection do not have any symptoms at all [53]. If HIV co-infected, such individuals may benefit from HSV-2 suppressive therapy not only through its effects on reducing herpes transmission and herpes reactivation, [54-56] but also through its salutary effects on HIV. The purpose of this multicentre, randomized, placebo-controlled clinical trial is therefore to answer the question, “Among adults co-infected with
HIV and HSV-2 who are not using chronic suppressive anti-HSV therapy and who are neither currently using nor deemed to require HAART, can oral valacyclovir 500 mg twice daily delay the time until the need for HAART initiation?

Methods

Study Design

The VALIDATE study is a multicentre, randomized, placebo-controlled, fully blinded, clinical trial of twice daily oral valacyclovir 500 mg versus placebo with the goal of delaying the need for initiating HAART among HIV, HSV-2 co-infected individuals who neither use nor require HAART, and who have not used chronic suppressive anti-HSV therapy for at least the 6 months prior to study initiation.

Study Objectives

The primary objective of this trial is to compare the time from enrolment to the primary endpoint of either a CD4 cell count ≤ 350 cells/mm$^3$ measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason, between adults with both stable untreated HIV and HSV-2 co-infection who are randomized to valacyclovir compared to those randomized to placebo.

Secondary objectives are as follows:

- To compare the annual rate of change in the absolute CD4 cell count between study arms.
- To compare the annual rate of change in the CD4 cell count percentage between study arms.
- To compare the median log$_{10}$ HIV viral load between study arms.
- To compare the rate of drug-related adverse events between study arms.
- To compare the median frequency of HSV reactivations per year between study arms.
- To compare the rate of acyclovir-resistant HSV between study arms.
- To compare quality of life between study arms.

A substudy will characterize plasma markers of inflammation in this cohort of HAART-naive HIV-infected patients and compare the levels of these markers between study arms.

Study Hypotheses

The primary hypothesis of the trial is that valacyclovir 500 mg orally twice daily will delay the time until HAART is initiated among adults co-infected by stable untreated HIV and HSV type 2 co-infection. The secondary hypotheses are that valacyclovir 500 mg orally twice daily is associated with a slower rate of change in both the absolute CD4 cell count and the CD4 cell count percentage, a lower median log$_{10}$ HIV viral load, a similar rate of drug-related adverse events, a lower frequency of HSV reactivations, a similar rate of acyclovir-resistant HSV, and improvements in quality of life compared with placebo.

Eligibility Criteria

Individuals will be eligible for the trial if they meet the following inclusion criteria:

- adult (aged 18 years or older or as per Local/Provincial Guidelines)
- documented HIV-1 infection (determined by EIA and Western blot)
- documented HSV-2 seropositivity (determined by ELISA during screening; see below)
- no use of chronic anti-HSV therapy for the past 6 months, and not anticipated to require chronic anti-HSV therapy during the study
- antiretroviral naïve (no more than 14 days of total prior ARV exposure)
- CD4 count within the 400-900 cells/mm$^3$ range (inclusive) on two consecutive occasions, with at least one measurement within 4 weeks of initiating trial
- does not meet recommendations for initiating ARV therapy according to current guidelines [57,58]

Chronic anti-HSV therapy refers to the regular, daily use of medications with anti-HSV activity (such as acyclovir, valacyclovir, famciclovir, ganciclovir, valganciclovir, cidofovir, foscarnet). It does not refer to the episodic use of short courses of these medications for treatment of isolated HSV flares for a few days at a time.

The exclusion criteria for this study are as follows:

- pregnancy or actively planning to become pregnant
- receiving chemotherapy, chronic steroid therapy or other immunomodulatory medications (e.g. interferon, azathioprine, methotrexate, TNF-alpha antagonists, etc.)
- Estimated creatinine clearance < 30 mL/min
- Other medical condition likely to cause death within 24 months
- Enrolled in a therapeutic vaccine or immunotherapy trial
- Enrolled in another trial investigating the impact of another intervention on HIV disease progression
- HIV elite controller (EC), phenotypically defined here as documented duration of HIV infection of ≥5 years, a persistent CD4 cell count ≥500 cells/mm$^3$, and a persistent plasma HIV viral load of < 1000 copies/mL in the absence of antiretroviral therapy [3,59-61]
A stringent, empiric definition of the EC phenotype will be used because previous reports have primarily characterized ECs on the basis of genetic and immune markers beyond the means of this study [3,59-61]. The heterogeneity of CD4 counts and viral loads in ECs implies that a more permissive definition may overlap considerably with the general HIV-infected population and risk introducing a selection bias.

### Study setting

The VALIDATE trial will be conducted in industrialized/middle-income country settings. The study will randomize 480 participants, 240 in each arm. Participants will be recruited from sites including clinical research sites of the CIHR Canadian HIV Trials Network (CTN), the Instituto de Pesquisa Clinica Evandro Chagas (IPEC) HIV/AIDS Clinical Research Center of the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil, and the Hospital Fernandez/Fundación Huesped in Buenos Aires, Argentina. The CTN is a nationwide partnership established in 1990 of over 30 clinical trial sites across Canada, including both university-affiliated and community-based HIV clinics, with extensive experience in conducting HIV clinical trials. Both the IPEC Centre in Rio and the Hospital Fernandez and affiliated Fundación Huesped in Buenos Aires are national reference centres for infectious disease research, care and training, and are experienced leaders in international HIV/AIDS clinical trials.

### Treatment Groups

Participants in the intervention group will receive oral valacyclovir 500 mg twice daily, the standard dose used for HSV-2 suppression in HIV-infected individuals [15,62]. Valacyclovir is safe and well tolerated, as evidenced by clinical trials, where side effects have been reported at rates no different from those of placebo, and clinical experience [54,55,63,64]. Individuals in the control arm will receive an odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily. Use of other anti-HSV medication (including topical acyclovir) during the trial is prohibited, except during treatment of herpes flares (described below).

### Randomization and blinding methods

Randomization is stratified by site to help account for variation in practice regarding HAART initiation guidelines are continuously under evaluation, and HIV treatment guidelines may change. However, a change will not threaten the integrity of the study for a number of reasons. First, guidelines on HAART initiation have recently been revised [6,9]. Recommendations to uniformly increase the treatment threshold above 350 cells/mm$^3$ in both industrialized and middle-income settings based on definitive clinical trial data are not anticipated during the course of the trial. Second, as described above, the primary endpoint of this study is a composite of not only meeting the current CD4 threshold of 350 cells/mm$^3$, but also the initiation of HAART for any reason, whichever occurs first. Finally, randomization in this trial will be stratified by site to help account for variation in practice regarding initiation of HAART across sites.

The secondary outcome measures to be compared between the two treatment groups include:

- Annual rate of change in CD4 count, calculated as the slope of participants’ CD4 count change/time
- Annual rate of change in the CD4 cell count percentage, calculated as the slope of the participants’ CD4 count percentage change over time

### Outcome Measures

The primary outcome is the time from baseline until reaching the primary endpoint, a composite of either a CD4 cell count ≤ 350 cells/mm$^3$ measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason, whichever occurs first. This endpoint was selected because reaching the treatment threshold for initiating HAART is an important clinical event signifying the need for lifelong therapy. The CD4 count of ≤ 350 cells/mm$^3$ must be confirmed by a second measurement to verify the CD4 count is within the treatment range before initiating therapy. The primary endpoint also includes the initiation of HAART for any reason, since patients who start HAART outside these guidelines are also committed to lifelong therapy. This group may include individuals who choose to start therapy at earlier stages of disease (e.g. because of high viral load set-point), and some who develop HIV-related complications (e.g. tuberculosis) at higher CD4 cell counts, among others. For example, women who initiate HAART during pregnancy primarily for the prevention of mother-to-child transmission of HIV, and hepatitis B co-infected individuals who initiate HAART primarily for the purposes of treating their hepatitis B infection, will also be considered to have met the primary endpoint. It was important not to restrict the primary endpoint to initiation of HAART alone, since some patients may not initiate HAART despite reaching treatment thresholds for reasons including patient anxiety, concerns about adherence, and lack of familiarity with guidelines [65].

HAART initiation guidelines are continuously under evaluation, and HIV treatment guidelines may change.
• Log_{10} plasma HIV viral load at 12, 24 and 36 months of follow-up
• Treatment-emergent adverse events and laboratory abnormalities (CBC, plasma creatinine)
• Frequency of episodes of symptomatic HSV reactivation at any anatomic site
• Proportion of microbiologically confirmed flares of HSV during the trial that are caused by laboratory-confirmed acyclovir-resistant HSV
• Overall quality of life as measured by the MOS-HIV questionnaire at each 6-monthly time point.

Duration of Study Participation
Study visits will occur every 3 months over 2 years of participant accrual and 3 years of follow-up. Once enrolled, participants will enter the follow-up period during which they will be treated with either valacyclovir or placebo, and undergo follow-up visits every 3 months. Follow-up for an individual participant will continue until the end of the 5-year study period unless the primary endpoint is reached first. This means that all participants will be followed until the 5-year trial ends, unless they reach a primary endpoint first.

Safety
Adverse events and serious adverse events will be assessed at each study visit, graded on a 4-point scale (Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events), and assessed for their relationship to the study medication/intervention. The Data Safety Monitoring Committee (DSMC) of the CIHR CTN will be responsible for safety monitoring in this trial, and will also conduct safety analyses based on serious adverse events every 6 months, and ad hoc when necessary. The DSMC consists of clinicians, biostatisticians and a community member, from Canada and the United States.

Adherence Assessments
Adherence will be assessed at each visit through pill counts and through a self-report questionnaire (modified from the ACTG Adherence Questionnaire) at each visit [66,67]. In addition, urine samples will be collected from all study participants at pre-planned visits, stored at -80°C, and tested for acyclovir by mass spectrometry [68] to obtain overall estimates of adherence or cross over. Testing will be performed at the conclusion of the trial to help maintain blinding.

Management of symptomatic herpes during the trial
If a clinical reactivation of herpes symptoms occurs during the trial, participants are instructed to continue their study drug, present for clinical assessment, have samples taken to attempt microbiologic confirmation of the diagnosis where resources permit, and consider optional open-label treatment. Although participants in the treatment arm may thus receive a total valacyclovir dose of up to 3 g per day for 5 days, this quantity remains well within the safe therapeutic window of this drug. Of note, the occurrence of herpes flares in a study participant does not in itself unblind the study, because a small proportion of individuals taking chronic suppressive anti-HSV medications can experience herpes reactivations. If HSV resistance is suspected, specimens will be tested for acyclovir resistance using a plaque reduction assay [69].

Ethical approval
Ethical approval was obtained from the Research Ethics Board of the primary study site, the University Health Network (REB# 09-0587-B), prior to commencement of study activities at any site. Each study site also obtained approval from the local research ethics board prior to initiation of the study at that site. The research is being conducted in accordance with the Declaration of Helsinki.

Sample Size Calculation
It is hypothesized that suppression of HSV-2 using valacyclovir will increase the time until participants’ CD4 counts reach ≤ 350 cells/mm³ or initiate HAART from the expected value of 2 years to 2.75 years (see justification below). Participants will be recruited over 2 years and followed over 3 years. Using a conservative estimate that 25% of the sample will be lost to follow-up on average half way through the 3-year follow-up period, the expected years of follow-up is 0.75 × 3 years + 0.25 × 1.5 years = 2.625 years overall. In order to detect a difference of 0.75 years with a two-sided α = 0.0492 (adjusted for multiple analyses by the method of O’Brien and Fleming) [70] and 80% power in a survival analysis, 240 individuals will be required in each study arm, or 480 participants overall [71].

The expected rate at which HIV disease would progress in HAART-untreated individuals was based on both a retrospective review of patient charts and the published literature. Among 142 patients with at least 3 CD4 counts before starting HAART, with baseline CD4 count > 400 cells/mm³ at the Toronto General Hospital Immunodeficiency Clinic, the median time from first presentation to reaching CD4 ≤ 350 cells/mm³ was 2.0 years (Raboud JM, Li M: personal communication). In the subset with higher baseline CD4 counts (> 500 cells/mm³), the median time was 2.5 years. Consistent with these findings, a published retrospective observational cohort study of 4268 HIV-infected individuals in the United Kingdom with baseline CD4 counts > 500 cells/mm³ also found the median time to until reaching CD4...
counts ≤ 350 cells/mm$^3$ or initiation of antiretroviral therapy was 2.5 years [72]. Both are consistent with the generally accepted rate of CD4 count decline of 50-60 cells/mm$^3$ per year [2,3]. Valacyclovir 500 mg twice daily is estimated to decrease HIV plasma viral load by 0.5 log copies/mL. In previous studies, the magnitude of increase in HIV viral load associated with HSV-2 infection and the reciprocal decrease with valacyclovir 500 mg twice daily therapy was 0.33-0.53 log$_{10}$ copies/mL [18,32,33,41,42]. Further, the impact on HIV viral load was more pronounced with time and in those with higher baseline CD4 counts. The median baseline CD4 counts in these trials were 226 (IQR 145-389) and 446 cells/mm$^3$ (IQR 334-628) respectively [41,42]. Among persons with higher baseline CD4 counts of 400-900 cells/mm$^3$, valacyclovir is anticipated to reduce HIV viral load by about 0.5 log$_{10}$ copies/mL. Data from large cohort studies of untreated HIV infection that correlate HIV viral load set-points with rates of CD4 cell decline [2,3] suggest that valacyclovir will attenuate the rate of CD4 count decline by 10 cells/mm$^3$/year. Over the 3-5 years of follow-up in this study, the treatment arm is thus expected to experience an overall attenuation in CD4 count decline of 30-50 cells/mm$^3$, roughly equivalent to the CD4 count decline seen in 9 months. The sample size calculation is based on a prolongation in the time until CD4 ≤ 350 or HAART initiation from 2 to 2.75 years. The Kaplan-Meier estimates of the proportion of ART-naïve patients who experience a fall in CD4 count to ≤ 350 cells/mm$^3$ or who start HAART in the UK study cited above are consistent with these figures [72].

Nine months is a clinically important difference in the time for HIV-infected patients to delay initiation of life-long HAART. During this time, patients could avoid the costs, toxicity risks, and resistance risks of ARVs. Because typical HAART regimens can cost $12000 per month compared with only $150 per month for valacyclovir, this strategy could result in an annual net savings of nearly $10000 per patient based on medication costs alone. Further, although the toxicity profile of current ARVs is significantly better than in earlier years of the HIV epidemic, long-term toxicities remain unknown because most of the agents in current use were approved within the last 5-10 years. The ARV resistance risks to be avoided are also considerable; in clinical trials evaluating efavirenz-based HAART regimens, the current ‘gold standard’ for first-line ARV therapy, 30-70% of the 15-20% patients experiencing virologic failure at one year have evidence of resistance to the NNRTI class of drugs, effectively eliminating the potential for using standard agents in this class thereafter [73-77]. Delaying HAART also provides time for patients to prepare psychologically for starting HAART, which is an important predictor of subsequent adherence [78,79]. Nine months is also the time between 3 quarterly appointments, allowing ample time for clinician and patient to prepare for HAART. Finally, although there is theoretical risk of developing drug-resistant HSV with chronic valacyclovir, this risk is minimal even in immunocompromised patients. Resistance rates have stayed stable at 5-6% despite increasing population exposure to related drugs over 2 decades, perhaps because it imposes a fitness cost on the virus [15,80-83]. Resistant HSV is occasionally seen in advanced HIV patients with persistent lesions despite therapy, not in asymptomatic shedding. For safety, those with frequent recurrences unresponsive to therapy during the trial will have their viral isolates tested for resistance.

**Interim Analysis**
A single interim efficacy analysis is planned when 50% of the study endpoints have occurred; or at 3.5 years of follow-up, whichever occurs first. The DSMC will be asked to advise on early discontinuation of the trial at this point if there is clear evidence of benefit or harm in the treatment arm as defined below, using a two-sided statistical significance threshold of 0.0054 and power of 80% [70]. This analysis will have sufficient power to determine whether the intervention arm can expect a prolongation of the primary outcome from 2 years to 3.42 years. Based on the modest impact of HSV-2 and valacyclovir on HIV viral load, it is unlikely that such clear evidence of benefit will be seen at this interim analysis.

**Primary Analysis**
The primary outcome of the trial is the time from baseline until reaching the primary endpoint, a composite of either a CD4 cell count ≤ 350 cells/mm$^3$ measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason, whichever occurs first. The primary analysis will be a proportional hazards model, stratified by site, which will estimate the relative risk of progression to this endpoint associated with valacyclovir. Participants who do not reach either endpoint will be censored at the date of last CD4 count. The primary analysis will be conducted at the conclusion of the trial using the α = 0.0492 level of significance. This significance level adjusts for one interim analysis of the data according to the method of O’Brien and Fleming [70].

**Secondary Analyses**
Random effects models will be used to compare the annual rate of change in the absolute CD4 cell count, the annual rate of change in the CD4 cell count percentage, and the median log10 HIV viral load between study
arms. The rate of drug-related adverse events per year of follow-up, the number of episodes of HSV reactivations per year occurring at any anatomic site, the proportion of microbiologically confirmed flares of HSV during the trial that are caused by laboratory-confirmed acyclovir-resistant HSV, and the median overall quality of life score [84] at each 6-monthly time point will be compared between groups using Wilcoxon rank sum tests. All analyses will be by intention to treat, meaning that all participants will be analysed in the groups to which they were randomized.

Efforts to ensure that the CD4 and other trial data are well collected include biannual investigator meetings to review study procedures, regular site monitoring visits, and electronic data checks at the CTN National Data Centre. Because the analyses on rates of change in CD4 will only include CD4 counts prior to HAART initiation, the usual problem in HIV clinical trials of missing data among patients doing poorly clinically and dropping out of the trial is not anticipated to be an issue. Patients doing poorly clinically will reach the primary outcome, and it is only their CD4 counts before this time that will be included in the analysis.

Subgroup Analyses
Three sets of subgroup analyses of the primary outcome will be performed. First, analysis will be conducted according to serological evidence of dual HSV-2 and HSV-1 infection, compared with only HSV-2 infection. These exploratory data will contribute to the emerging literature on the prognostic significance of HSV-1 in HIV co-infection [85]. Second, subgroup analyses will also be performed to determine whether participants with higher levels of adherence achieve greater benefits than those with lower adherence, recognizing that such associations may be partially driven by unmeasured confounders such as health-seeking behaviours. Third, subgroup analyses will also be performed according to country (Canada vs Brazil vs Argentina) since small differences related to clinical practice patterns, gender mix, clade or unknown factors may exist.

Discussion
Given that HSV-2 is known to increase HIV viral load, that biological mechanisms of this interaction have been identified, and that pharmacologic suppression of HSV-2 has been shown to cause reciprocal decreases in HIV viral load, the hypothesis underlying the VALIDATE trial is that valacyclovir 500 mg twice daily may attenuate HIV disease progression and delay the need for initiating HAART in HIV-1, HSV-2 co-infected adults. Some data further suggest that acyclovir and, by extension, related drugs like valacyclovir, may have direct anti-HIV activity [86,87]. Some investigators have already advocated for all HIV patients to be routinely screened for HSV-2, with all co-infected individuals being offered chronic suppressive therapy in the hopes of attenuating rates of CD4 count decline [15]. Because acyclovir and its pro-drugs are safe, well-tolerated, and widely available, their use in this setting is realistic if benefit can be shown. However, type-specific HSV serologic testing is not yet routinely available, and anti-HSV drugs add to pill burden and cost, so demonstration of their effectiveness in randomized, controlled clinical trials is necessary before recommending widespread use. Although the Partners in Prevention trial recently demonstrated that HSV-2 suppression with acyclovir 400 mg twice daily results in a modest decrease in HIV disease progression in a cohort of co-infected adults in Sub-Saharan Africa, [45] the VALIDATE trial will examine this question in industrialized and middle-income countries where HIV clade, comorbid conditions, and standards of HIV care differ. Further, the intervention in the current trial is valacyclovir, the pro-drug of acyclovir, which has improved bioavailability relative to acyclovir [52].

It is recognized that HIV treatment guidelines are continuously under evaluation. In the time since the VALIDATE trial was designed, some panels have recommended that HAART should be initiated earlier, at the CD4 cell count threshold of 500 cells/mm³ instead of 350 cells/mm³ [6,9]. However, other guideline panels reviewing the same data have not reached the same conclusion, [7,8] suggesting there remains clinical equipoise regarding the optimal timing for initiating therapy.

This ongoing debate should not threaten the scientific integrity of the VALIDATE study for several reasons. First, the primary endpoint of this study was intentionally designed as a composite of not only meeting the CD4 threshold of 350 cells/mm³, but also the initiation of HAART for any reason, including patient or provider preference for earlier treatment, whichever occurs first. Second, randomization in this trial will be stratified by site to ensure that variation in practice regarding initiation of HAART across sites is distributed equally between treatment arms. Importantly, because no definitive clinical trial addressing the question of when to start therapy at thresholds of 350 cells/mm³ or higher is anticipated within the next several years, the primary objective of the VALIDATE trial remains highly clinically relevant. Even in an era when therapy has been broadly recommended at a CD4 threshold of 350 cells/mm³, the median CD4 count at treatment initiation in industrialized countries has been 200-300 because of costs, patient preference, and concerns about toxicities, adherence and resistance. If shown to be beneficial, HSV-2 suppression could thus offer important salutary
effects to individuals deemed eligible for HAART in the interim period while arrangements are made for medication coverage and while patients are counseled about the risks and benefits of antiretroviral therapy.

A related concern is that delays in the time until initiation of HAART could theoretically result in greater population-level risks of onward HIV transmission owing to increased population viral load. If demonstrated to be effective, use of the VALIDATE intervention will thus require careful consideration of its broader implications, and physicians will need to balance the personal clinical priorities of their patients with those of society at large. However, implementation of the VALIDATE intervention would not preclude bolstering of other interventions to curb the spread of HIV infection. Further mitigating this concern is the hypothesis that HSV-2 suppression, if implemented using an appropriate regimen and/or in appropriate populations, could have meaningful effects on decreasing HIV transmission, even if existing acyclovir-based clinical trials have been unsuccessful thus far [88,89].

Valacyclovir for HSV-2 suppressive therapy is an attractive potential intervention for patients with HIV-1, HSV-2 co-infection at early stages of HIV disease, and the VALIDATE trial is hypothesized to validate this potential for clinical benefit.

Acknowledgements
This clinical trial is supported by a grant from the Canadian Institutes of Health Research and by the CIHR Canadian HIV Trials Network. DHST receives research fellowship support from the Canadian Institutes of Health Research. RK receives salary support from the Canada Research Chair in Health Research and by the CIHR Canadian HIV Trials Network. The funding agencies had no role in the design of the research. RK receives salary support from the Canada Research Chair in Health Research and by the CIHR Canadian HIV Trials Network. DHST This clinical trial is supported by a grant from the Canadian Institutes of Health Research and by the CIHR Canadian HIV Trials Network. DHST receives research fellowship support from the Canadian Institutes of Health Research. RK receives salary support from the Canada Research Chair Program. JMR and SLW receive salary support from the Ontario HIV Treatment Network. The funding agencies had no role in the design of the trial or writing of this manuscript.

Author details
1 University Health Network, 585 University Ave., 13N - 1323, Toronto, Ontario, trial or writing of this manuscript.

Authors’ contributions
DHST and SLW conceived the original idea for the trial. DHST, SLW, RK, JMR, BG and PC contributed to the design of the trial. JMR and DHST performed the sample size calculations for the trial. DHST wrote the original version of the manuscript, and all authors critically reviewed and approved the final version.

Competing interests
The authors declare that they have no competing interests.

Received: 1 October 2010 Accepted: 24 November 2010 Published: 24 November 2010

References
1. Stein DS, Konvick JA, Vermund SH: CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992, 165(2):352-363.
2. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R et al: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126(12):946-954.
3. Rodriguez B, Sethi AK, Chevuru VK, Mackay W, Bosch RJ, Kihatana M, Boswell SL, Mathews WC, Bangsberg DR, Martin J et al Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006, 296(12):1498-1506.
4. O’Brien TR, Blattner WA, Waters D, Eyster E, Hilgarter MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS et al: Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophillia Cohort Study. JAMA 1996, 276(2):105-110.
5. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272(5265):1167-1170.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2009, 1-161.
7. Guidelines: Clinical Management and Treatment of HIV Infected Adults in Europe. AIDS Clinical Society, 2009.
8. Gazzard BG, Anderson J, Babiker A, Boiffio M, Brook G, Brough G, Churchill D, Cromarty B, Dass S, Fisher M et al: British HIV Association Guidelines for the treatment of HIV-1 infected adults with antiretroviral therapy 2008. HIV Med 2008, 9(8):563-608.
9. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardin G, Teleneti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS et al: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304(3):321-333.
10. El-Sadr WM, Lundgren JD, Neaton JD, Gardin F, Abrams D, Arndino RC, Babiker A, Burman W, Cumeck N, Cohen CJ et al: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283-2296.
11. Santos FC, de Oliveira SA, Setubal S, Camacho LB, Faillace T, Leste JQ, Velarde LG, Group HSVII. Seroepidemiological study of herpes simplex virus type 2 in patients with the acquired immunodeficiency syndrome in the city of Niteroi, Rio de Janeiro, Brazil, Memorias do Instituto Oswaldo Cruz 2006, 101(3):315-319.
12. Chu K, Jamton S, Pepin J, Covian F, Mahakkanukrauh B, Surrent R, Robinson NJ, Deslandes S, Frost E, Chaisilwattana P et al: Association between HSV-2 and HIV-1 viral load in semen, cervico-vaginal secretions and genital ulcers of Thai men and women. International Journal of STD & AIDS 2006, 17(10):681-686.
13. Cowan FF, Pascoe SJS, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, Robinson NJ, Latif AS, Bassett MT, Wilson D et al: Association of genital shedding of herpes simplex virus type 2 and HIV-1 among women in rural Zimbabwe. AIDS 2006, 20(2):261-267.
14. Ramaswamy M, Sabin C, McDonald C, Smith M, Taylor C, Genetti AM: Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and serocidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons. Sexually Transmitted Diseases 2006, 33(2):96-101.
15. Stick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clinical Infectious Diseases 2006, 43(9):347-356.
16. Romanowski B, Myziuk LN, Walmley SL, Trotter S, Singh AE, Houston S, Joffe M, Chiu I: Seroepidemiology and Risk Factors for Herpes Simplex Virus Infection in a Population of HIV-Infected Patients in Canada. Sex Transm Dis 2009, 36(1):10-14.
17. Brown EL, Wald A, Hughes JP, Morrow RA, Krantz E, Mayer K, Buchbinder S, Koblin B, Celum C. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. American Journal of Epidemiology 2016, 184(7):733-741.
18. Gray RH, Wawer MJ, Sewankambo NK, Serwadda D, Li C, Moulton LH, Lutalo T, Wabwire-Mangen F, Meehan MP, Ahmed S et al: Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. Rakai Project Team, AIDS 1999, 13(15):2113-2123.
19. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women:
systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20(1):73-83.
20. del Mar Puyades Rodriguez M, Obasi A, Nsasra F, Todd J, Brown D, Chagalula J, Malenby D, Boss M, Gass K, Hayes R: Herpes simplex type 2 infection increases HIV incidence: a prospective study in rural Tanzania.[see comment]. AIDS 2002, 16(3):451-462.
21. Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Karim SA: The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. [see comment]. AIDS 2005, 19(3):333-339.
22. Reynolds SJ, Ridbud AR, Shepherd ME, Zenfilter NM, Fonck K, Ngugi EN, Keli F, MacDonald KS, Reynolds SJ, Risbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS, Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Karim SA: Prior herpes simplex virus type 1 infection as a risk factor for HIV infection. JAMA 1998, 280(7):1049-1050.
23. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M: Herpes simplex virus type 2 infection among male Zimbabwean factory workers. Journal of Infectious Diseases 1999, 180(5):1459-1465.
24. Holmberg SD, Stewart JA, Gerber AR, Byers RH, Lee FK, O'Reilly PM, Nahmias AJ: Prior herpes simplex virus type 1 infection as a risk factor for HIV infection. JAMA 1991, 265(7):1049-1050.
25. Kaur R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M, et al.: Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial.[see comment], JAMA 2004, 291(21):2555-2562.
26. Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2004, 35(5):435-445.
27. Wald A, Corey L: How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis?[comment]. Journal of Infectious Diseases 2003, 187(10):1513-1521.
28. McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Cey L, Parsonnet J, Burke RL, Katzenstein D: Prevalence and incidence of herpes simplex virus type 2 infection among male Zambian sex workers. Journal of Infectious Diseases 1999, 180(5):1459-1465.
29. Watson-Jones D, Weiss HS, Ruszkova M, Chagalula J, Basile K, Mugeye K, Tantos C, Ross D, Everett D, Clayton T, et al.: Effect of herpes simplex virus type 2 infection on sexual transmission and transmission: a review of two overlapping epidemics. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2004, 35(5):435-445.
30. Wald A, Corey L: How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis?[comment]. Journal of Infectious Diseases 2003, 187(10):1513-1521.
31. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Morettie S, Cowan F, Casapia M, Ortiz A, Fuchs J, et al.: Effect of acyclovir on acquisition in herpes simplex virus 2 infected seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371(9603):2109-2119.
32. Watson-Jones D, Weiss HS, Ruszkova M, Chagalula J, Basile K, Mugeye K, Tantos C, Ross D, Everett D, Clayton T, et al.: Effect of herpes simplex virus type 2 infection on incidence of HIV among women in Tanzania[see comment]. New England Journal of Medicine 2008, 358(15):1560-1571.
33. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins J, Hughes JP, et al.: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010, 362(3):242-253.
34. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, et al.: Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009, 15(8):866-892.
35. Mole L, Rehik S, Margolis D, Holodniy M: The impact of active herpes simplex virus type 1 and herpes simplex virus type 2 infection on human immunodeficiency virus infection. Journal of Infectious Diseases 1997, 176(3):766-770.
36. Schacker T, Zej H, Hu H, Shaughnessy M, Corey L: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. Journal of Infectious Diseases 2002, 186(12):1718-1725.
37. Gray RH, Lu X, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Lutalo T, Kiwanuka N, Kiogyi G, Nakumaga F, et al.: Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. Journal of Infectious Diseases 2004, 189(7):1209-1215.
38. Schacker T, Ryncarz AJ, Goodard J, Diem K, Shaughnessy M, Corey L: Frequency of recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998, 280(1):61-66.
39. Mosca JD, Bednarik DP, Raj NB, Rosen CA, Sadosrski JS, Haselnete WA, Pitha PM: Herpes simplex virus type 1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987, 325(6099):67-70.
simplex virus infection in HIV-infected individuals: two randomized trials. International Journal of STD & AIDS 2002, 13(1):12-21.
56. Corey L, Wald A, Patel R, Sacks SL, Tyding SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, et al: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350(1):11-20.
57. Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2008.
58. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walsmey S, Cahn P, Fischl MA, Gatelle JM, Hirsch MS, et al: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300(5):555-570.
59. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332(4):201-208.
60. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Dernarfe JF, Montefiori D, Orenstein JM, Fox C, Schrager UK, et al: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332(2):209-216.
61. Vicenzi E, Poli G: Regulation of HIV expression by viral genes and cytokines. J Leukoc Biol 1994, 56(3):528-334.
62. Workowski K, Berman SM: Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2006, 55(RR-11):1-94.
63. Tyding SK, Baker D, Snowden W: Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. Journal of Infectious Diseases 2002, 186(Suppl 1):S40-46.
64. Patel R, Bodsworth NJ, Woolley P, Peters B, Vellinga G, Saari S, Gibb A, Robinson J: Valacyclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Gentamicin Med 1997, 73(2):105-109.
65. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, Gifford AL, Liu HH, Nakazono TT, Morton S, et al: Evaluation and predictors of highly active antiretroviral therapy use with long-term HIV in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000, 25(2):115-123.
66. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12(3):255-266.
67. Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA: Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr 2007, 44(6):402-409.
68. Kesar A, Gilek E, Georgakakos K, Kazanas M, Pandori I: Selective and rapid liquid chromatography-negative-ion electrospray ionization mass spectrometry method for the quantification of valacyclovir and its metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 864(1-2):78-86.
69. Collins P, Appleyard G, Oliver NM: Sensitivity of herpes virus isolates from acyclovir clinical trials. Am J Med 1992, 73(A1):380-382.
70. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 1979, 35(3):549-556.
71. Dupont WD, Plummer WD: Power and sample size calculations. A review and computer program. Control Clin Trials 1990, 11(2):116-128.
72. HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 46(3):275-278.
73. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer IWA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, et al: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New England Journal of Medicine 2004, 350(18):1850-1861.
74. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleman JMAH, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, et al: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.[see comment]. JAMA 2004, 292(2):191-201.
75. Gallant JE, DeJesus E, Artsis J, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chik S, Enejosa J, et al: Tenofovir DF, emtricitabine, and efavirenz vs. didavudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354(3):251-260.
76. Riddler SA, Haurich R, DiRienzo AG, Pfefferle L, Powderly WG, Klingman KL, Ganem KW, George T, Rooney Jr, Brisz B, et al: Class-sparing regimens for initial treatment of HIV-1 infection.[see comment]. New England Journal of Medicine 2008, 358(20):2095-2106.
77. MacArthur RD, Novak RM, Peng C, Chen L, Xiang Y, Hullisiek R, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, et al: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPACA 058 FIRST Study): a long-term randomised trial. Lancet 2006, 368(9553):2125-2135.
78. Ballou L, Kooy J, Silverman A, Tasca GA, Angel JB, Macpherson PA, Garber G, Cooper CL, Cameron DW: A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care 2006, 18(7):830-838.
79. Nordqvist O, Sedgberg B, Tully MP, Sonneberg A, Lindblad AK: Assessing and achieving readiness to initiate HIV medication. Patient Education and Counseling 2006, 62(1):21-30.
80. Coen DM: Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 1994, 2(12):481-485.
81. Honda M, Okuda T, Hasegawa T, Kurokawa M, Shiakå K, Matsuo K, Komatsuzaki M, Nirimura M: Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir-resistance of herpes simplex virus type 2. Antivar Chem Therap 2001, 12(4):233-239.
82. Levin MJ, Bacon TH, Leary J: Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clinical Infectious Diseases 2004, 39(Suppl 1):S248-257.
83. Reyes M, Shak NS, Graber JM, Nisenbaum R, Wetherell NT, Fukuda K, Reeves WC: Task Force on Herpes Simplex Virus. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Archives of Internal Medicine 2003, 163(1):76-80.
84. Wu AW: MOS-HIV Health Survey Users Manual. 1999 [http://chpts.chc. ucla.edu/assessment/pdf/asessments/MOS-HIV%20Users%20Manual%2 ODraft.pdf].
85. Tan D, Kaul R, Walmsey S: Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex type 1 and HIV? Canadian Journal of Infectious Diseases and Medical Microbiology 2009, 20(1):e1-7.
86. Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, Brichacek B, Elliott J, Fromentin E, Shattock R, Anton P, et al: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008, 4(3):260-270.
87. McMahan MA, Silicano JD, Lai J, Liu JD, Severs JT, Silicano RF, Kohli RM: The antherapeutic drug acyclovir inhibits HIV replication and selects the VSV reverse transcriptase multidrug resistance mutation. J Biol Chem 2008, 283(4):3129-3139.
88. Bowser S, Ma L: Calculating the contribution of herpes simplex virus type 2 to epidemicizing HIV incidence: treatment implications. Clinical Infectious Diseases 2004, 39(Suppl 1):S240-247.
89. Baggaley RF, Griffin JT, Chapman R, Hollingsworth TD, Nagot N, Delany S, Mayauro P, de Wolf F, Fraser C, Ghani AC, et al: Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. AIDS 2009, 23(8):1005-1013.

Cite this article as: Tan et al., Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. Trials 2010 11:113.